Medications for Influenza B Virus

12 results

  • oseltamivir

    (OSELTAMIVIR)
    Alembic Pharmaceuticals Inc.
    Oseltamivir phosphate is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older within 48 hours of symptom onset. It is also used for prophylaxis in individuals 1 year and older. Vaccination is recommended annually and resistance may impact effectiveness.

  • oseltamivir phosphate

    (Oseltamivir Phosphate)
    Neolpharma Inc
    Oseltamivir phosphate is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older, symptomatic for no more than 48 hours. It is also used for prophylaxis of influenza in individuals 1 year and older.

  • oseltamivir phosphate

    (Oseltamivir Phosphate)
    Asclemed USA, Inc.
    Oseltamivir phosphate for oral suspension is indicated for treating acute, uncomplicated influenza A and B in patients 2 weeks and older within 48 hours of symptoms. It is also indicated for prophylaxis of influenza A and B in patients 1 year and older.

  • oseltamivir phosphate

    (Oseltamivir Phosphate)
    NuCare Pharmaceuticals,Inc.
    Oseltamivir Phosphate is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older within 48 hours of symptom onset, and for prophylaxis in patients aged 1 year and older. It is not a substitute for annual vaccinations.

  • oseltamivir phosphate

    (Oseltamivir phosphate)
    Novadoz Pharmaceuticals LLC
    Oseltamivir phosphate capsules are indicated for the treatment of influenza A and B in patients aged 2 weeks and older, symptomatic for no more than 48 hours, and for prophylaxis in patients 1 year and older. It is not a substitute for annual influenza vaccination.

  • oseltamivir phosphate

    (Oseltamivir Phosphate)
    Lupin Pharmaceuticals Inc
    Oseltamivir phosphate for oral suspension is indicated for treating acute influenza A and B in patients aged 2 weeks and older within 48 hours of symptom onset, and for prophylaxis in individuals 1 year and older. It is not a substitute for annual vaccination and has specific use limitations.

  • oseltamivir phosphate

    (oseltamivir phosphate)
    Novadoz Pharmaceuticals LLC
    Oseltamivir phosphate for oral suspension is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older with symptoms for no more than 48 hours, and for prophylaxis in patients aged 1 year and older. It is not a substitute for vaccination.

  • oseltamivir phosphate

    (oseltamivir phosphate)
    Redpharm Drug
    Oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older, and for prophylaxis in those aged 1 year and older. It is not a substitute for annual flu vaccination and has limitations regarding drug resistance and specific populations.

  • oseltamivir phosphate

    (Oseltamivir phosphate)
    Redpharm Drug
    Oseltamivir phosphate capsules are indicated for treating acute, uncomplicated influenza A and B in patients 2 weeks and older, symptomatic for no more than 48 hours, and for prophylaxis in patients 1 year and older. They are not a substitute for vaccination and have specific limitations for use.

  • oseltamivir phosphate

    (OSELTAMIVIR PHOSPHATE)
    Aurobindo Pharma Limited
    Oseltamivir phosphate oral suspension is indicated for treating acute, uncomplicated influenza A and B in patients aged 2 weeks and older within 48 hours of symptoms onset, and for prophylaxis in patients 1 year and older. It is not a substitute for vaccination and may have limitations due to resistance.